# Characterizing vitamin B6 pathway dependency in acute myeloid leukemia

> **NIH NIH R37** · COLD SPRING HARBOR LABORATORY · 2024 · $417,241

## Abstract

PROJECT SUMMARY/ABSTRACT
Acute myeloid leukemia (AML) is one of the most devastating blood cancers, and it affects around one million people and
results in 147,000 deaths per year worldwide. AML is characterized by the abnormal production of myeloid lineage of blood
cells and the rapid growth of leukemia blasts in bone marrow and peripheral blood. AML is a very aggressive cancer, and
it progresses rapidly and AML patients become fatal within weeks to months. Currently, therapeutic options for AML are
very limited. Only about 35% of AML patients under 60 years-old and 10% over 60 years-old benefit from standard
chemotherapy. Thus, there is an urgent and unmet medical need to develop new therapeutic approaches particularly
combination therapies with advanced efficacy and reduced toxicity for AML patients. Our long-term goals of the proposed
research are to study abnormal vitamin pathways as metabolic dependencies in AML, to investigate critical regulators of
vitamin pathways in supporting AML cell aberrant proliferation, and to identify druggable therapeutic targets in AML. We
have recently uncovered vitamin B6 pathway as a novel dependency in AML. Based on this finding, we hypothesize that
vitamin B6 pathway is a specific anti-leukemia target and has promising therapeutic potential to treat AML. To assess the
hypothesis, we have identified multiple key enzymes in vitamin B6 dependent metabolic pathways essential for AML cell,
but not for normal bone marrow hematopoietic stem and progenitor cell and immune cell, proliferation. Depletion of these
key enzymes exhibited robust inhibition on AML proliferation. We have also validated vitamin B6 pathway as a
pharmacologically actionable pathway and showed that vitamin B6 pathway inhibitors exhibit promising therapeutic
efficacy in multiple genetically engineered AML models in vivo. These robust preliminary data encourage us to pursue three
Specific Aims to further characterize vitamin B6 pathway: 1) to characterize both upstream and downstream regulators of
vitamin B6 pathway in AML; 2) to evaluate the synergy between vitamin B6 pathway and BCL-2 in AML therapeutics to
further enhance its efficacy; and 3) to perform functional genomics screens to identify vitamin B6 pathway synergistic
effectors in AML. We propose to study AML from the aspect of vitamin B6 pathway and metabolic programming, a process
which is novel and essential for AML cell proliferation. The proposed research will be focusing on both mechanistic
understanding and therapeutic targeting of vitamin B6 pathway in association with different synergistic effectors in AML.
The major goals of this proposal are to identify the unique vitamin B6 upstream regulators and downstream effectors as
well as its synergistic effectors to treat AML. The proposal is significant because it will not only uncover the underlying
mechanism but also pinpoint therapeutic targets to synergistically enhance the anti-leukemia effects in AML.

## Key facts

- **NIH application ID:** 10760275
- **Project number:** 5R37CA276938-02
- **Recipient organization:** COLD SPRING HARBOR LABORATORY
- **Principal Investigator:** LINGBO ZHANG
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $417,241
- **Award type:** 5
- **Project period:** 2023-01-05 → 2027-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10760275

## Citation

> US National Institutes of Health, RePORTER application 10760275, Characterizing vitamin B6 pathway dependency in acute myeloid leukemia (5R37CA276938-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10760275. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*